Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Joshi

Showing results (441-450 of 455) with videos related to

Pageof 46
Sort By:
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
American Journal of Human Genetics|May 5, 2018
A Mixed-Effects Model for Powerful Association Tests in Integrative Functional GenomicsYu-Ru Su, Chongzhi Di, Stephanie Bien, et al.
The Lancet. Global Health|August 23, 2020
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trialVijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, et al.
Journal of the National Cancer Institute|September 2, 2024
Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinomaVanita Noronha, Vijay Maruti Patil, Nandini Menon, et al.
Cancer Cell|November 20, 2018
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain MutationsKanika Bajaj Pahuja, Thong T Nguyen, Bijay S Jaiswal, et al.
The National Medical Journal of India|December 3, 2022
Cancer care continuum at a tertiary care centre in India during the Covid-19 pandemic and nationwide lockdown: Healthcare delivery through telemedicineAnant Gokarn, Amit Joshi, Tabassum Wadasadawala, et al.
JNCI Cancer Spectrum|July 27, 2024
Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancersAnant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, et al.
Cancer|June 1, 2019
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancerVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Frontiers in Oncology|August 1, 2022
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS TrialMagnus Nilsson, Halla Olafsdottir, Gabriella Alexandersson von Döbeln, et al.
Indian Journal of Cancer|March 28, 2022
Expert survey on management of prostate cancer in India: Real-world insights into practice patternsGanesh Bakshi, Hemant Tongaonkar, Sanjai Addla, et al.
Pageof 46

Showing results (441-450 of 455) with videos related to

Sort By:
Pageof 46
Breast Cancer Research : BCR|September 13, 2014
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Chad J Creighton, Nrusingh C Biswal, et al.
American Journal of Human Genetics|May 5, 2018
A Mixed-Effects Model for Powerful Association Tests in Integrative Functional GenomicsYu-Ru Su, Chongzhi Di, Stephanie Bien, et al.
The Lancet. Global Health|August 23, 2020
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trialVijay Patil, Vanita Noronha, Sachin Babanrao Dhumal, et al.
Journal of the National Cancer Institute|September 2, 2024
Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinomaVanita Noronha, Vijay Maruti Patil, Nandini Menon, et al.
Cancer Cell|November 20, 2018
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain MutationsKanika Bajaj Pahuja, Thong T Nguyen, Bijay S Jaiswal, et al.
The National Medical Journal of India|December 3, 2022
Cancer care continuum at a tertiary care centre in India during the Covid-19 pandemic and nationwide lockdown: Healthcare delivery through telemedicineAnant Gokarn, Amit Joshi, Tabassum Wadasadawala, et al.
JNCI Cancer Spectrum|July 27, 2024
Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancersAnant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, et al.
Cancer|June 1, 2019
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancerVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
Frontiers in Oncology|August 1, 2022
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS TrialMagnus Nilsson, Halla Olafsdottir, Gabriella Alexandersson von Döbeln, et al.
Indian Journal of Cancer|March 28, 2022
Expert survey on management of prostate cancer in India: Real-world insights into practice patternsGanesh Bakshi, Hemant Tongaonkar, Sanjai Addla, et al.
Pageof 46